IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval

By News Health
3 months Ago

(MedPage Today) — The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.
The tablets are indicated…

Source link : https://www.medpagetoday.com/nephrology/generalnephrology/114955

Author :

Publish date : 2025-04-03 16:51:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

NHS Access Issues Driving Down Childhood Vaccine Uptake

Most on Wegovy a Year Later; Food Label Weight Stigma; Make Your Own GLP-1 Drugs?

Proton Pump Inhibitors and Hypertension; AI Fetal Cardiac Scans; 'Work Diet'

A Neanderthal-shaped skull may explain why some people get headaches

Fixable Factors Help Drive Disparities in Access to COVID Treatment

Synthetic Nicotine Storms Onto the Vaping Scene